This is in line with results in human MM, with TP53 mutations in 57% of cell lines vs 2% of NDMM, and DUSP2 mutations in 10% of cell lines versus 5% NDMM based on an WES analysis of 69 human myeloma cell lines (https://www.keatslab.org) and the CoMMpass dataset. This evidence concerns the gene DUSP2 and Miyoshi myopathy.